# US 2021/0172954 A1 · Diagnostic and prognostic marker for prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172954 A1
- Document ID: US20210172954A1
- Status: Published application
- Kind: A1
- Application number: 17/035,318
- Filed: 2020-09-28
- Published: 2021-06-10
- Earliest claimed: 2013-03-15
- Assignees: Onconostic Technologies, Inc.
- Applicants: Onconostic Technologies, Inc.
- Inventors: Partha RAY
- Web page: https://patentgrep.com/patent/US20210172954A1

## CPC

- G01N 33/57555: of the prostate
- A61B 10/0241: {for prostate}
- A61B 34/10: Computer-aided planning, simulation or modelling of surgical operations
- A61N 5/103: {Treatment planning systems}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61B 2017/00274: {Prostate operation, e.g. prostatectomy, turp, bhp treatment}
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein are methods for determining a diagnosis and/or prognosis for prostate cancer using the ratio of FOXC1:FOXA1 in a sample obtained from a subject.

## Claims

### Claim at position 1

1-53. (canceled)

### Claim 54

A method for treating a subject based on the prognosis of a prostate cancer in a subject diagnosed as having prostate cancer, comprising:
(i) obtaining a tissue sample from said subject, wherein said tissue sample comprises prostate cancer cells;
(ii) determining the level of FOXA1 protein or nucleic acid in said tissue sample,
(iii) determining the level of FOXC1 protein or nucleic acid in said tissue sample,
(iv) calculating the ratio of said FOXC1 protein or nucleic acid to said FOXA1 protein or nucleic acid;
(v) comparing said ratio to a comparable FOXC1:FOXA1 ratio in a reference population of samples comprising prostate cancer cells in which a prognostic outcome is associated with each of the reference population samples;
(vi) identifying said subject as having a poor prognosis relative to the prognostic outcome when the FOXC1:FOXA1 ratio of the subject is equal to or greater than a FOXC1:FOXA1 cutoff ratio, and identifying said subject as having a good prognosis relative to the prognostic outcome when the FOXC1:FOXA1 ratio of the subject is less than the FOXC1:FOXA1 cutoff ratio, wherein the FOXC1:FOXA1 cutoff ratio corresponds to at least the 50th percentile of FOXC1:FOXA1 ratios of the reference population; and
(vii) treating said subject by discontinuing, maintaining, initiating, or modifying at least one anti-cancer therapy based on the prognosis identified in step (vi).

### Claim 55 (depends on 54)

The method of claim 54, wherein the prostate cancer comprises a cancer selected from the group consisting of an adenocarcinoma, a small cell carcinoma, and a prostatic sarcoma.

### Claim 56 (depends on 54)

The method of claim 54, wherein the level of FOXA1 protein and FOXC1 protein is determined in the tissue sample.

### Claim 57 (depends on 54)

The method of claim 54, wherein the level of FOXA1 nucleic acid and FOXC1 nucleic acid is determined in the tissue sample.

### Claim 58 (depends on 57)

The method of claim 57, wherein the FOXA1 nucleic acid is FOXA1 mRNA and the FOXC1 nucleic acid is FOXC1 mRNA.

### Claim 59 (depends on 54)

The method of claim 54, wherein the FOXC1:FOXA1 cutoff ratio corresponds to at least the 90th percentile of FOXC1:FOXA1 ratios of the reference population.

### Claim 60 (depends on 54)

The method of claim 54, wherein the prognostic outcome is selected from the group consisting of survival duration, event-free survival, and relapse-free survival.

### Claim 61 (depends on 54)

The method of claim 54, wherein said method further comprises:
(vii) developing and implementing a treatment plan based on the prognostic identification of step (vi).

### Claim 62 (depends on 61)

The method of claim 61, wherein the treatment plan comprises (a) discontinuing at least one anti-cancer therapy for a subject having a good prognosis, (b) maintaining at least one anti-cancer therapy for a subject having a good prognosis, (c) initiating at least one anti-cancer therapy for a subject having a good prognosis, (d) discontinuing at least one anti-cancer therapy for a subject having a poor prognosis, or (e) initiating at least one anti-cancer therapy for a subject having a poor prognosis.

### Claim 63 (depends on 61)

The method of claim 61, wherein the treatment plan comprises increasing the frequency, duration, or dose of at least one anti-cancer therapy for a subject having a poor prognosis.

### Claim 64

A method for treating a subject diagnosed with a prostate cancer, comprising:
(i) obtaining a tissue sample from said subject, wherein said tissue sample is suspected of comprising prostate cancer cells;
(ii) determining the level of FOXA1 protein or nucleic acid in said tissue sample,
(iii) determining the level of FOXC1 protein or nucleic acid in said tissue sample,
(iv) calculating the ratio of said FOXC1 protein or nucleic acid to said FOXA1 protein or nucleic acid;
(v) comparing said ratio to a comparable FOXC1:FOXA1 ratio in a reference population of samples known to comprise prostate cancer cells;
(vi) identifying said subject as having a prostate cancer when the FOXC1:FOXA1 ratio of the subject is equal to or greater than a FOXC1:FOXA1 cutoff ratio, and identifying said subject as not having a prostate cancer when the FOXC1:FOXA1 ratio of the subject is less than the FOXC1:FOXA1 cutoff ratio, wherein the FOXC1:FOXA1 cutoff ratio corresponds to at least the 20th percentile of FOXC1:FOXA1 ratios of the reference population; and
(vii) treating the subject diagnosed with a prostate cancer by a chemotherapeutic agent or performing a surgical resection of the prostate, surrounding tissues, or distant tissues in which metastasis are expected or confirmed.

### Claim 65 (depends on 64)

The method of claim 64, wherein the prostate cancer comprises a cancer selected from the group consisting of an adenocarcinoma, a small cell carcinoma, and a prostatic sarcoma.

### Claim 66 (depends on 64)

The method of claim 64, wherein the level of FOXA1 protein and FOXC1 protein is determined in the tissue sample.

### Claim 67 (depends on 64)

The method of claim 64, wherein the level of FOXA1 nucleic acid and FOXC1 nucleic acid is determined in the tissue sample.

### Claim 68 (depends on 67)

The method of claim 67, wherein the FOXA1 nucleic acid is FOXA1 mRNA and the FOXC1 nucleic acid is FOXC1 mRNA.

### Claim 69 (depends on 64)

The method of claim 64, wherein the FOXC1:FOXA1 cutoff ratio corresponds to at least the 75th percentile of FOXC1:FOXA1 ratios of the reference population.

### Claim 70 (depends on 64)

The method of claim 64, wherein said method further comprises:
(vii) developing and implementing a treatment plan based on the diagnostic identification of step (vi).

### Claim 71 (depends on 70)

The method of claim 70, wherein the treatment plan comprises (a) initiating radiation therapy, (b) initiating chemotherapy, or (c) a partial surgical resection of the prostate cancer.

### Claim 72

A method for determining and implementing a treatment plan in a subject diagnosed as having a prostate cancer, said method comprising:
(i) obtaining a tissue sample from said subject, wherein said tissue sample comprises prostate cancer cells;
(ii) determining the level of FOXA1 protein or nucleic acid in said tissue sample,
(iii) determining the level of FOXC1 protein or nucleic acid in said tissue sample,
(iv) calculating the ratio of said FOXC1 protein or nucleic acid to said FOXA1 protein or nucleic acid;
(v) comparing said ratio to a comparable FOXC1:FOXA1 ratio in a reference population of samples known to comprise prostate cancer cells; and
(vi) developing and implementing a treatment plan based on the comparison of step (v) for said subject as having a prostate cancer when the FOXC1:FOXA1 ratio of the subject is equal to or greater than a FOXC1:FOXA1 cutoff ratio, wherein the FOXC1:FOXA1 cutoff ratio corresponds to at least the 20th percentile of FOXC1:FOXA1 ratios of the reference population, wherein the treatment plan includes initiating a chemotherapy, initiating a radiation therapy, and surgical resection of the prostate, surrounding tissues, or distant tissues in which metastasis are expected or confirmed.

### Claim 73 (depends on 72)

The method of claim 72, wherein the prostate cancer comprises a cancer selected from the group consisting of an adenocarcinoma, a small cell carcinoma, and a prostatic sarcoma.

### Claim 74 (depends on 72)

The method of claim 72, wherein the level of FOXA1 protein and FOXC1 protein is determined in the tissue sample.

### Claim 75 (depends on 72)

The method of claim 72, wherein the level of FOXA1 nucleic acid and FOXC1 nucleic acid is determined in the tissue sample.

### Claim 76 (depends on 75)

The method of claim 75, wherein the FOXA1 nucleic acid is FOXA1 mRNA and the FOXC1 nucleic acid is FOXC1 mRNA.

### Claim 77 (depends on 72)

The method of claim 72, wherein the treatment plan comprises an action selected from the group consisting of discontinuing at least one anti-cancer therapy, initiating at least one anti-cancer therapy, maintaining the dosage, frequency, or duration of at least one anti-cancer therapy, increasing the dosage, frequency, or duration of at least one anti-cancer therapy, and reducing the dosage, frequency, or duration of at least one anti-cancer therapy.
